GeoPharma has reached agreement with Consolidated Pharmaceutical Group (CPG) and have entered into a Settlement and Mutual Release Agreement and other documents on September 4, 2009, settling all claims against the other. GeoPharmareached settlement through its subsidiary, American Antibiotics (AA Parties).
Reportedly, the litigation relates to certain agreements entered into between American Antibiotics and CPG, whereby American Antibiotics acquired certain business assets of CPG for the production of Beta-Lactam Antibiotics as well as all CPG’s rights, title and interest in various pharmaceutical Abbreviated New Drug Applications (ANDAs) associated with a Baltimore manufacturing facility.
Baltimore manufacturing facility owned and formerly operated by CPG dedicated for the production of Beta-Lactam Antibiotics under an ANDA Sale and Purchase Agreement (ASPA) dated February 7, 2005, and entered into a lease for the Baltimore Facility dated July 19, 2005.
The company said that the September 2006 lawsuit brought by the company alleged that CPG breached the ASPA & Lease with certain misrepresentations related to the ANDA’s and failed to perform all the required improvements and modifications to the Facility under the Lease. Consolidated with American Antibiotic’s lawsuit was a separate action filed against it by CPG, alleging that American Antibiotics failed to pay rent due and owing under the Lease.
Under the terms of settlement: the AA Parties and the CPG Parties agreed to execute a new three year lease for the facility with renewable options. The new lease also confers upon American Antibiotics a three year option to purchase the facility.
Further, all prior agreements, financial obligations, understandings or other commitments between the parties were terminated, superseded and extinguished with the execution of the Settlement Documents. However, the company will file an 8-K on 9/8/09 with the relevant Settlement Documents attached.
Mandeep Taneja, chief legal counsel at GeoPharma, said: “We are very pleased with the settlement of the lawsuit and the elimination of the additional expenditures associated with the litigation. The settlement will allow us to make further progress toward the production of Beta Lactam antibiotics which is in line with our core business model.”